SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~July~~October 2428, 2003

BIOGEN, INC.

(Exact name of registrant as specified in its charter)


Massachusetts	0-12042	04-3002117

(State or other jurisdiction of incorporation	(Commission File Number)	(IRS Employer Identification No.)


14 Cambridge Center, Cambridge, MA		02142

(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (617) 679-2000

TABLE OF CONTENTS

	ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE.
	Item 7. Financial Statements and Exhibits.
	ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
	Item 12. Disclosure of Results of Operations and Financial Condition.
SIGNATURES
EXHIBIT INDEX
EX-99.1 PRESS RELEASE DATED 7-24-03
EX-99.1 PRESS RELEASE DATED OCTOBER 28, 2003

~~ITEM 5~~Item 7. ~~OTHER~~Financial ~~EVENTS~~Statements ~~AND~~and ~~REGULATION FD DISCLOSURE~~Exhibits.

On July 24, 2003, the Registrant and Elan Corporation, plc publicly disseminated a joint press release announcing that the Phase III induction trial of ANTEGREN® (natalizumab) did not meet the primary endpoint of “response” as defined by a 70-point decrease in the Crohn’s Disease Activity Index at week 10. There were no notable differences in the overall rates of side effects between natalizumab and placebo treatment groups through week 12. The information contained in the press release is incorporated herein by reference and filed as Exhibit 99.1 hereto.

	(c)		Exhibits.

	99.1		The Registrant’s Press Release dated October 28, 2003.

~~ITEM~~ This 7.press ~~FINANCIAL~~release ~~STATEMENTS~~is ~~AND~~being ~~EXHIBITS~~furnished pursuant to Item 12 of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

~~(c) Exhibits~~Item 12. Disclosure of Results of Operations and Financial Condition.

~~99.1~~ The attached press release includes information with respect to the Registrant’s ~~Press~~operating ~~Release~~earnings, ~~dated~~operating ~~July 24~~earnings per share, ~~2003~~operating net income and other operating results, all of which are non-GAAP financial measures. Management utilizes these non-GAAP financial measures to monitor and evaluate ongoing operating results and trends and to gain an understanding of the comparative operating performance of the Registrant. Management believes that these measures provide useful information to investors regarding the Registrant’s financial condition and results of operations because they exclude non-operational and unusual activities or transactions that are not necessarily relevant to an understanding of the Registrant’s business or the prospects for the Registrant’s future performance.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		BIOGEN, INC.
		BIOGEN, INC. (Registrant)
		(Registrant)
Date: October 28,2003		/s/ Anne Marie Cook
Date: July 29, 2003		/s/ Anne Marie Cook
		Anne Marie Cook Vice President, Chief Corporate Counsel
		Anne Marie Cook Vice President, Chief Corporate Counsel

EXHIBIT INDEX

Exhibit
Number		Description
99.1		The Registrant’s Press Release dated ~~July~~October 2428, 2003.

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Filing Compare · BIOGEN IDEC MA INC